Skip to main content
SpringerLink
Log in

Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment

  • Comment
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia MT (2020) Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism—the EMIRA study. J Clin Endocrinol Metab 105:2060–2067

    Article  Google Scholar 

  2. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr (2016) The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:1889–1916

    Article  Google Scholar 

  3. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, Beuschlein F, Rossi GP, Nishikawa T, Morganti A et al (2020) Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 38:1919–1928

    Article  CAS  Google Scholar 

  4. Armanini D, Strasser T, Weber PC (1985) Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes. J Hypertens 3:S157-159

    CAS  Google Scholar 

  5. Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW (1985) In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol 23:341–347

    Article  Google Scholar 

  6. Armanini D, Sabbadin C, Donà G, Clari G, Bordin L (2014) Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Exp Opin Pharmacother 15:909–912

    Article  CAS  Google Scholar 

  7. Mantero F, Armanini D, Opocher G (1978) Effect of spironolactone and potassium canrenoate on plasma renin activity and plasma and urinary aldosterone in primary aldosteronism. Aldosterone antagonists in clinical medicine. In: Proceedings of the Searle symposium, Nice. Excerpta Medica,vol 103, pp 1629–1635

  8. Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N, Sartorato P (2005) Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one-month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J Endocrinol Invest 28:236–240

    Article  CAS  Google Scholar 

  9. Armanini D, Fiore C, Pellati D (2007) Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 50:e69-70

    Article  CAS  Google Scholar 

  10. Fischer E, Beuschlein F, Degenhart C, Endres S, Beuschlein F, Rencke M (2012) Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn’s Registry. Clin Endocrinol 76:473–477

    Article  CAS  Google Scholar 

  11. Wehling M, Kuhls S, Armanini D (1989) Volume regulation of human lymphocytes by aldosterone in isotonic media. Am J Physiol 257:E170-174

    CAS  PubMed  Google Scholar 

  12. Wehling M, Armanini D, Strasser T, Weber PC (1987) Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. Am J Physiol 252:E505-507

    Article  CAS  Google Scholar 

  13. Calò L, Zaghetto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martire G, Fiore C, Armanini D (2004) Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22phox in human mononuclear leukocytes. J Clin Endocrinol Metab 89:1973–1976

    Article  Google Scholar 

  14. Ichikawa S, Tajima Y, Sakamaki T, Matsuo H, Kogure M, Hirano Y, Yagi S, Murata K (1984) Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism. Jpn Circ J 48:1184–1196

    Article  CAS  Google Scholar 

  15. Seifarth C, Trenkel S, Schobel H, Hahn E, Hensen H (2002) Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinols 57:457–465

    Article  CAS  Google Scholar 

  16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717

    Article  CAS  Google Scholar 

  17. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone post-acute myocardial infarction heart failure efficacy and Survival Study Investigators. Eplerenone a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Sophie Armanini for English editing.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author information

Authors and Affiliations

  1. Department of Medicine (DIMED)-Endocrinology, University of Padua, Via Ospedale 105, 35128, Padua, Italy

    D. Armanini, C. Sabbadin & M. Boscaro

Authors
  1. D. Armanini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Sabbadin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Boscaro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Armanini.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Armanini, D., Sabbadin, C. & Boscaro, M. Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment. J Endocrinol Invest 44, 2009–2010 (2021). https://doi.org/10.1007/s40618-021-01500-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-021-01500-z

Search

Navigation